- Home
- MDGL vs TPG Comparison
MDGL vs TPG Comparison
Compare MDGL & TPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDGL | TPG |
|---|---|---|
| Founded | 2011 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 8.9B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDGL | TPG |
|---|---|---|
| Price | $435.92 | $40.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $674.45 | $64.27 |
| AVG Volume (30 Days) | 327.9K | ★ 4.1M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.27% |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,133,000.00 | N/A |
| Revenue This Year | $58.70 | N/A |
| Revenue Next Year | $46.88 | $19.04 |
| P/E Ratio | ★ N/A | $106.82 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $265.00 | $37.52 |
| 52 Week High | $615.00 | $70.38 |
Technical Indicators
Market Signals| Indicator | MDGL | TPG |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 28.90 |
| Support Level | $416.43 | N/A |
| Resistance Level | $446.51 | $46.33 |
| Average True Range (ATR) | 15.97 | 1.98 |
| MACD | 2.59 | 0.09 |
| Stochastic Oscillator | 56.64 | 14.08 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.